160 related articles for article (PubMed ID: 35562126)
21. [The application of complexed PSA and its relative indexes in the diagnosis of prostate cancer].
Chen ZH; Zhao J; Wu JM; Xiao CG
Zhonghua Nan Ke Xue; 2003 Feb; 9(1):36-9. PubMed ID: 12680329
[TBL] [Abstract][Full Text] [Related]
22. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
24. [Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages].
Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
[No Abstract] [Full Text] [Related]
25. Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less.
Sasaki M; Ishidoya S; Ito A; Saito H; Yamada S; Mitsuzuka K; Kaiho Y; Shibuya D; Yamaguchi T; Arai Y
Urology; 2014 Nov; 84(5):1163-7. PubMed ID: 25443923
[TBL] [Abstract][Full Text] [Related]
26. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
[TBL] [Abstract][Full Text] [Related]
27. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
28. Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer.
Avci S; Onen E; Caglayan V; Kilic M; Sambel M; Oner S
Arch Ital Urol Androl; 2020 Apr; 92(1):1-6. PubMed ID: 32255313
[TBL] [Abstract][Full Text] [Related]
29. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
Naya Y; Fritsche HA; Cheli CD; Stamey TA; Bartsch G; Brawer MK; Childs S; Taneja SS; Lepor H; Partin AW; Sokoll LJ; Chan DW; Babaian RJ
Urology; 2003 Dec; 62(6):1058-62. PubMed ID: 14665355
[TBL] [Abstract][Full Text] [Related]
30. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
31. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
32. [Significance of prostate central gland/total gland volume ratio combined with PSA in the diagnosis of prostate cancer patients].
Guo ZF; Lu XW; Yang F; Wu JW; Wang H; He C
Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2836-2839. PubMed ID: 31550812
[No Abstract] [Full Text] [Related]
33. Correlation between prostate volume and prostate-specific antigen in Nigerian men with symptomatic histologically-diagnosed benign prostatic hyperplasia.
Aigbe E; Irekpita E; Ogbetere FE; Alili UI
Niger J Clin Pract; 2022 Sep; 25(9):1523-1528. PubMed ID: 36149214
[TBL] [Abstract][Full Text] [Related]
34. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia.
Coban S; Doluoglu OG; Keles I; Demirci H; Turkoglu AR; Guzelsoy M; Karalar M; Demirbas M
Aging Male; 2016 Jun; 19(2):124-7. PubMed ID: 26872869
[TBL] [Abstract][Full Text] [Related]
35. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
36. Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
Naya Y; Stamey TA; Cheli CD; Partin AW; Sokoll LJ; Chan DW; Brawer MK; Taneja SS; Lepor H; Bartsch G; Childs S; Fritsche HA; Babaian RJ
Urology; 2002 Oct; 60(4 Suppl 1):36-41. PubMed ID: 12384161
[TBL] [Abstract][Full Text] [Related]
37. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
38. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
[TBL] [Abstract][Full Text] [Related]
39. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
[TBL] [Abstract][Full Text] [Related]
40. The establishment and evaluation of a new model for the prediction of prostate cancer.
Wang Q; Li YF; Jiang J; Zhang Y; Liu XD; Li K
Medicine (Baltimore); 2017 Mar; 96(11):e6138. PubMed ID: 28296726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]